Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 133-156 , April 1998

Chemotherapy in advanced pancreatic adenocarcinoma

  • C. Kollmannsberger

      Affiliations

    • University of Tuebingen Medical Center, Department of Haematology-Oncology (Head: Prof. L. Kanz, M.D.), Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany
    • ,
  • H.D. Peters

      Affiliations

    • University of Hannover Medical School, Department of Immunopharmacology, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
    • ,
  • U. Fink

      Affiliations

    • Corresponding Author InformationCorrespondence: U. Fink, Abtl. Chirurgische Onkologie, Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Muenchen, Germany.
    • Technical University of Muenchen, Klinikum rechts der Isar, Section of Surgical Oncology, Ismaningerstr. 22, 81675 Muenchen, Germany

References 

  1. Devesa SS, Blot WJ, Stone BJ, Miller B, Tarone R, Fraumeni J. Recent cancer trends in the United States. J Natl Cancer Inst. 1995;87:175–182
  2. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin. 1995;45:8–30
  3. Niederhuber J, Brennan MF, Menck HR. The national cancer data base on pancreatic cancer. Cancer. 1995;76:1671–1677
  4. Hermanek P. Staging of exocrine pancreatic carcinoma. Eur J Surg Oncol. 1991;17:167–172
  5. Russell RCG. Surgical resection for cancer of the pancreas. Baillière's Clin Gastroenterol. 1990;4:889–915
  6. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–190
  7. Ahlgren JD. Epidemiology and risk factors in pancreatic cancer. Semin Oncol. 1996;23:241–250
  8. Casper ES. Pancreatic cancer: how can we progress?. Eur J Cancer. 1993;29A(Suppl. 2):171–172
  9. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995;31A:882–887
  10. Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev. 1975;2:193–214
  11. Burris HA, Moore MJ, Anderson J, et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413
  12. Cullinan S, Moertel CG, Wieand HS, et al.  A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer. 1990;65:2207–2212
  13. Bertheault-Cvitkovic F, Levi F, Soussan S, et al.  Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. Eur J Cancer. 1993;29A:1851–1854
  14. Tajiri H, Yoshimori M, Okazaki N, Miyaji M. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology. 1991;48:18–21
  15. Ardalan B, Sparling L, Livingstone A, et al.  Phase II trial of high-dose 24-hour infusion of 5-fluorodeoxyuridine (FUDR) in patients with operable pancreatic cancer (previously failed 5-FU and Gemzar®). In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 282a; (abstract 999)
  16. Matsushima Y, Kanzawa F, Hoshi A, et al.  Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol. 1985;14:104–107
  17. Seifert P, Baker L, Reed M, et al.  Comparison of continuously infused 5-fluorouracil with bolus injection in the treatment of patients with colorectal carcinoma. Cancer. 1981;48:2565–2568
  18. Lokich JL, Ahlgren JD, Gullo JJ, Philipps JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7:425–432
  19. DeCaprio JA, Mayer RJ, Gonin R, Arbuck S. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991;9:2128–2133
  20. Rubin J, Gallagher J, Schutt A, et al.  Phase II trial of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinomas. In: 4th edition. Proc Am Soc Clin Oncol. 11:1992;p. 170; (abstract 496)
  21. Weinerman B, MacCormick R. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am J Clin Oncol. 1994;17:467–469
  22. Bolli E, Saccomanno S, Mondini G, et al.  5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. Cancer Chemother Pharmacol. 1995;35:339–342
  23. Louvet Ch, Beerblock K, de Gramont A, et al.  High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study. Eur J Cancer. 1993;29A:1217.0000
  24. Crown J, Casper ES, Botet J, Murray P, Kelsen D. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol. 1991;9:1682–1686
  25. Schilder RJ, Paul AR, Walczak J, et al.  Phase II trial of PALA/5-fluorouracil (5-FU) in pancreatic cancer. In: 4th edition. Proc Am Soc Clin Oncol. 9:1990;p. 109; (abstract 422)
  26. Morell LM, Bach A, Richman SP, Goodman P, Fleming T, MacDonald J. A phase II multiinstitutional trial of low-dose N-(phosphonacetyl)-l-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. Cancer. 1991;00:363–366
  27. Rosvold E, Schilder R, Walczak J, et al.  Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol. 1992;29:305–308
  28. Pazdur R, Ajani JJ, Abbruzzese JL, et al.  Phase II evaluation of 5-fluorouracil and recombinant interferon-α2A in previously untreated patients with pancreatic adenocarcinoma. Cancer. 1992;70:2073–2076
  29. Tian E, Ardalan B, Benedetto P, et al.  A phase II study of short term protracted infusion of high-dose 5-fluorouracil with leucovorin and low-dose phosphonylacetyl-aspartic acid (PALA) in pancreatic carcinoma. In: 4th edition. Proc Am Soc Clin Oncol. 11:1992;p. 184; (abstract 550)
  30. Cascinu S, Fedeli A, Luzi Fedeli S, Catalano G. 5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. Ann Oncol. 1993;4:83–84
  31. Bernhard H, Jäger-Arand E, Bernhard G, et al.  Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha 2A: results of a phase II trial. Br J Cancer. 1995;71:102–105
  32. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J. A phase II trial of 5-fluorouracil, leucovorin and recombinant alpha-2b-Interferon in advanced adenocarcinoma of the pancreas. Cancer. 1992;70:1864–1866
  33. Schneider CJ, Vaughn DJ, Holyroyde C, et al.  Phase II trial of 5-FU, leucovorin and interferon alpha 2A in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCGTG) trial. In: 4th edition. Proc Am Soc Clin Oncol. 14:1995;p. 189; (abstract 433)
  34. Grogan L, Sotos GA, Allegra CJ. Leucovorin modulation of fluorouracil. Oncology. 1993;7:63–72
  35. Ardalan B, Sridhar KS, Benedetto P, et al.  A phase I,II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-l-aspartic acid in patients with advanced malignancies. Cancer. 1991;68:1242–1246
  36. Taylor CW, Modiano MR, Woodson ME, Marcus SG, Alberts DS, Hersh EM. A phase I trial of fluorouracil, leucovorin, and recombinant interferon α-2b in patients with advanced malignancy. Semin Oncol. 1992;19(Suppl. 3):185–190
  37. Grem I, Allegra C, McAtee N, et al.  Phase I study of interferon alpha 2a, 5-fluorouracil and high-dose leucovorin in metastatic gastrointestinal carcinoma. In: 4th edition. Proc Am Soc Clin Oncol. 9:1990;p. 70; (abstract 272)
  38. Moore M, Kaiser L, Ehrlichmann C, Field R, Fire S. A phase I clinical and pharmacologic study of 5-fluorouracil (5-FU), leucovorin and interferon for patients with gastrointestinal adenocarcinoma. In: 4th edition. Proc Am Soc Clin Oncol. 10:1991;p. 111; (abstract 313)
  39. Basile M, Rougier P, Ducreux M, et al.  A phase II study of 5-FU continuous infusion and CDDP in measurable advanced carcinoma of the pancreas. In: 4th edition. Proc Am Soc Clin Oncol. 10:1991;p. 149; (abstract 461)
  40. Kellogg C, Gordon C, Vaitkevicius V, et al.  PACE chemotherapy (platinol, ARA-C and caffeine) with continuously infused 5-FU in the treatment of advanced pancreatic cancer. In: 4th edition. Proc Am Soc Clin Oncol. 12:1993;p. 216; (abstract 654)
  41. Wils JA, Kok T, Wagener DJT, Selleslags J, Duez N. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer. 1993;29A:203–204
  42. Hubbard K, Pazdur R, Ajani JA, et al.  Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol. 1992;15(6):524–527
  43. Schwartz G, Casper E. A phase II trial of doxorubicin HCL liposome injection in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 1995;13:77–82
  44. Altavilla G, Adamo V, Alafaci E, et al.  High dose epirubicin in the treatment of advanced adenocarcinoma of the pancreas. Eur J Cancer. 1991;27(Suppl. 2):74; (abstract 419)
  45. Topham C, Glees J, Rawson NSB, Woods E, Coombs R. Randomized trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer. 1991;64:179–181
  46. Aoki K, Shimada Y, Okazaki N, et al.  A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas. Eur J Cancer. 1992;28A:1590
  47. Kornek G, Radere M, Schenk Th, et al.  Phase I/II trial of dexverapamil, epirubicin and granulocyte-macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma. Cancer. 1950;76:1356–1362
  48. Abad A, Masuti B, Camps C, et al.  Epirubicin plus a calmodulin inhibitor (trifluperazine) activity in advanced pancreatic adenocarcinoma. Eur J Cancer. 1994;30A:000; (abstract 1043)
  49. Vaughn CB, Salmon SE, Fleming TR. Phase II evaluation of esorubicin (4′deoxydoxorubicin) in pancreatic adenocarcinoma. In: A Southwest Oncology Group Study. 4th edition. Invest New Drugs. 8:1990;p. 81–85
  50. Taylor SA, Fleming T, von Hoff DD, et al.  Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group Study. Invest New Drugs. 1990;8:77–80
  51. Mahjoubi M, Rougier Ph, Oliviera J, Herait P, Tigand J-M, Droz JP. Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer. Cancer Invest. 1994;12(4):403–405
  52. Jenkins TR, Tangen C, MacDonald JS, Weiss G, Chapman R, Hantel A. A phase II trial of piroxantrone in adenocarcinoma of the pancreas. In: A Southwest Oncology Group Study. 4th edition. Invest New Drugs. 11:1993;p. 329–331
  53. Schein P, Lavin P, Moertel C, Frytak S, Hahn R. Randomized phase II clinical trial of adriamycin, methotrexate and actinomycin D in advanced measurable pancreatic carcinoma. Cancer. 1978;42:19–22
  54. Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986;4:425–439
  55. DeSimone PA, Gams R, Bartolucci A. Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group trial. Cancer Treat Rep. 1986;70:929–930
  56. Loehrer PJ, Williams SD, Einhorn LH, Ansahri R. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol. 1985;3:367–372
  57. Ajani JA, Abbuzzese L, Goudeau P, et al.  Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol. 1988;6:1703–1707
  58. Gastrointestinal Tumor Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer. 1989;64:2010–2013
  59. Cerny T, Martinelli G, Goldhirsch A, et al.  Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol. 1991;117(Suppl. 4):135–138
  60. Wils J, Kok T, Wagener DJT, Francois E, Selleslags J, Duez N. Phase II trial with ifosfamide in pancreatic cancer. Eur J Cancer. 1993;29A:290.000
  61. Whitehead R, Jacobson J, Brown T, Taylor S, Weiss G, Macdonald J. Phase II trial of paclitaxel and granulocyte colony stimulating factor in patients with pancreatic carcinoma: a Southwest Group Study. J Clin Oncol. 1978;15:2414–2419
  62. Rougier Ph, De Forni M, Adenis A, et al.  Phase II study of taxotere (RP 56976, docetaxel) in pancreatic adenocarcinoma (PAC). In: 4th edition. Proc Am Soc Clin Oncol. 13:1994;p. 200; (abstract 587)
  63. Pazdur R, Meropol NJ, Casper ES, et al.  Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs. 1996;13:355–358
  64. Miller KG, Loehrer PJ, Picus J, et al.  A phase II trial of LY 231514 in patients with unresectable pancreatic cancer. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 297a; (abstract 1060)
  65. Loh K, Stuart K, Cohn A, et al.  A phase II trial of Thymidaq (AG 337) in patients with adenocarcinoma of the pancreas. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 265a; (abstract 938)
  66. Sakata Y, Wakui A, Nakao I, et al.  A late phase II study of irinotecan (CPT-11) in advanced pancreatic cancer. In: 4th edition. Proc Am Soc Clin Oncol. 12:1993;p. 211; (abstract 633)
  67. Wagener DJT, Verdonk H, Dirix LY, et al.  Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol. 1995;6:129–132
  68. Sugarman SM, Pazdur R, Daughterty K, et al.  A phase II trial of topotecan (TPT) for the treatment of unresectable pancreatic cancer (PC). In: 4th edition. Proc Am Soc Clin Oncol. 13:1994;p. 224; (abstract 684)
  69. Carmichael J, Fink U, Russell RCG, et al.  Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101–105
  70. Casper ES, Green MR, Kelsen DP, Heelan R, Brown T, Flambaum C. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29–34
  71. Rothenberg ML, Moore MJ, Cripps MC, et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347–353
  72. Storniolo AM, Enas NH, Brown CA, Schilsky R. Treatment investigational new drug program for Gemzar® (gemcitabine HCL) in patients with pancreas cancer (PaCa). In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 306a; (abstract 1088)
  73. Kaue SB. Docetaxel (taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin Oncol. 1995;22(Suppl. 4):30–33
  74. Abbruzzese JL, Evans D, Gravel D, Markowitz A, Patt Y, Pazdur R. Docetaxel (D), a potentially active agent for patients with pancreatic adenocarcinoma (PA). In: 4th edition. Proc Am Soc Clin Oncol. 14:1995;p. 221; (abstract 561)
  75. Asbury RF, Cnaan A, Johnson L, Harris J, Taentz SD, Haller DG. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, Vp-16, aclacinomycin or spirogermanium in metastatic pancreatic cancer. Am J Clin Oncol. 1994;17:166–169
  76. Moore DF, Pazdur R, Abbruzzese JL, et al.  Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol. 1994;5:286–287
  77. Casper ES, Schwartz GK, Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 1992;10:205–209
  78. Brown TD, Goodman PJ, Fleming TR, Baker LH, MacDonald JS. Phase II trial of menogaril in adenocarcinoma of the pancreas: a Southwest Oncology Group Study. Invest New Drugs. 1991;9:77–78
  79. Kraut EH, Fleming T, Macdonald JS, Spiridonidis CH, Bradof JE, Baker LH. Phase II trial of merbarone in pancreatic carcinoma. Am J Clin Oncol. 1993;16(4):327–328
  80. Trump DL, Hathorn JA, Grochow LB, Spriggs D, Eble ML, Hohneker JA. Phase II evaluation of the AMAP, 773U82 mesylate, in pancreatic cancer. Invest New Drugs. 1994;12(4):273–276
  81. Linke K, Pazdur R, Ajani J, et al.  Phase II trial of amonafide in advanced pancreatic carcinoma. In: 4th edition. Proc Am Soc Clin Oncol. 10:1991;p. 146; (abstract 452)
  82. Leichman CG, Tangen C, Macdonald JS, Leimert T, Fleming TR. Phase II trial of amonafide in advanced pancreas cancer: a Southwest Oncology Group trial. Invest New Drugs. 1993;11:219–221
  83. Moore M, Maroun J, Robert F, et al.  Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. Invest New Drugs. 1993;11:61–65
  84. Gröhn P, Heinenen E, Kumpulainen E, et al.  Oral carmofur in advanced gastrointestinal cancer. Am J Clin Oncol. 1990;13(6):477–479
  85. Brown T, Williams R, Kelley S, Sterbenz K, Wilkins B, Coble D. A phase II trial of MBY-28175 in advanced pancreatic carcinoma. In: 4th edition. Proc Am Soc Clin Oncol. 13:1994;p. 219; (abstract 664)
  86. Kilton LJ, Benson AB, Greenberg A, et al.  Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. In: An Illinois Cancer Center Study. 4th edition. Invest New Drugs. 10:1992;p. 201–204
  87. Marsh RDW, Manyam V, Bewsher C, Youngblood M. Circadian rhythm modulated 5-FUDR infusion with megace in the treatment of advanced pancreatic cancer. J Surg Oncol. 1994;57:25–29
  88. Kraut EH, Fleming T, Segal M, Niedhart J, Behrans B, MacDonald J. Phase II study of pibenzimol in pancreatic cancer: a Southwest Oncology Group Study. Invest New Drugs. 1991;9:95–96
  89. Patel SR, Kvols LK, Rubin J, et al.  Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs. 1991;9:53–58
  90. Carlson RW, Doroshow JH, Odujinrin OO, Flam M, Malec M, Lamborn K. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs. 1990;8:387–389
  91. Shiomoto GM, Kuo S, Wade J, et al.  Phase II study of trimetrexate glucuronate in the treatment of advanced carcinoma of the pancreas. In: 4th edition. Proc Am Soc Clin Oncol. 11:1992;p. 184; (abstract 549)
  92. Guy J, Fleming Th, Pollock T, et al.  5-Day vinblastine infusion for pancreatic adenocarcinoma. Invest New Drugs. 1990;8:205–206
  93. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. 4th edition. Philadelphia, PA: J.B. Lippincott; 1993;p. 849–882
  94. The Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozotocin plus mitomycin-C plus fluorouracil. J Clin Oncol. 1986;4:1794–1798
  95. Bukowski R, Balcerzak S, O'Bryan R, Bonnet J, Chen T. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotozin for advanced pancreatic cancer. Cancer. 1983;52:1577–1582
  96. O'Byrne K, Salisbury A, Macaulay V, et al.  5-Fluorouracil, folinic acid and hydroxyurea chemotherapy in gastrointestinal and pancreatic tumours. Br J Cancer. 1994;67(Suppl. 21):21.00
  97. Scheithauer W, Funovics J, Mueller C, Ludwig H. Sequential high-dose methotrexate, 5-fluorouracil and doxorubicin for treatment of advanced pancreatic cancer. J Cancer Res Clin Oncol. 1990;116:132–133
  98. Harstrick A, Köhne-Wömper C, Preusser P, et al.  A phase II study of the combination of PALA, MTX and 5-FU in advanced pancreatic cancer. In: second edition. Proc Am Soc Clin Oncol. 12:1993;p. 219; (abstract 665)
  99. Redei I, Green F, Hoffman J, Weiner L, Scher R, O'Dwyer P. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. Invest New Drugs. 1994;12:319–321
  100. Isacoff WH, Reber H, Tompkins R, et al.  Continuous infusion (CI) 5-fluorouracil (5-FU), calcium leucovorin (LV), mitomycin-C (Mito C), and dipyridamole (D) treatment for patients with locally advanced pancreatic cancer. In: second edition. Proc Am Soc Clin Oncol. 14:1995;p. 198; (abstract 471)
  101. Burch PA, Ghosh C, Schroeder G, et al.  A phase II evaluation of continuous-infusion (CI) 5-FU, leucovorin (LV), mitomycin-C (MMC) and oral dipyridamole (D) in advanced measurable pancreatic cancer (PC): a NCCTG trial. In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 211; (abstract 484)
  102. Verhees S, Flechtner H. Behandlung des fortgeschrittenen Pankreascarcinoms mit 5-Fluorouracil, 4-Epidoxorubicin und Mitomycin C (FEM II). Onkologie. 1990;13:50–52
  103. Topham C, Glees J, Coombs R, et al.  Comparison of single agent epirubicin and 5-FU/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. Oncology. 1993;50:78–83
  104. Rothman H, Cantrell JE, Lokich J, et al.  Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. In: A Mid-Atlantic Oncology Program Study. second edition. Cancer. 68:1991;p. 264–268
  105. Auerbach M, Wampler GL, Jacob J, et al.  Treatment of advanced pancreatic carcinoma with a combination of protracted infusional fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study. In: second edition. Proc ASCO. 12:1993;p. 224; (abstract 687)
  106. Andre T, Lotz JP, Bouleuc C, et al.  Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol. 1996;7:173–178
  107. Underhill CR, Highley MS, Parnix FX, et al.  Epirubicin [E], Cisplatin [C] and infusional 5-FU [F], (ECF)—an active regimen in pancreatic carcinoma (PC). In: second edition. Proc Am Soc Clin Oncol. 15:1996;p. 203; (abstract 453)
  108. Munzone E, Nole F, de Braud F. ECF (epirubicin, cisplatin, fluorouracil) in pancreatic carcinoma (PC): a promising approach. In: second edition. Proc Am Soc Clin Oncol. 16:1997;p. 298a; (abstract 1062)
  109. Heinemann V, Wilke H, Possinger K, et al.  Activity and tolerability of gemcitabine plus cisplatin in patients with advanced metastatic pancreatic carcinoma. Eur J Cancer. 1997;33(Suppl. 8):274.000
  110. Gattani A, Mandeli J, Chesser MR, Bruckner HW. An active biochemical modulation regimen for advanced adenocarcinoma of the pancreas. In: second edition. Proc Am Soc Clin Oncol. 11:1992;p. 193; (abstract 587)
  111. Raymont E, Louvet C, de Gramont A, et al.  Clinical benefit improvement with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma. Eur J Cancer. 1997;33:686–697
  112. Kelsen DP, Hudis C, Niedzwiecki D, et al.  A phase III comparison trial of streptozotocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991;68(Suppl. 5):965–969
  113. Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, Baker LH. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. Cancer. 1993;7:322–325
  114. Moertel CG, Rubin J, O'Connell MJ, Schutt A, Wieand H. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol. 1986;4:1053–1057
  115. Dougherty JB, Kelsen D, Kemeny N, Magill G, Botet J, Niedzwiecki D. Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. J Natl Cancer Inst. 1989;81:1735–1738
  116. Palmer K, Kerr M, Knowles G, Cull A, Carter D, Leonard R. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994;81:882–885
  117. Glimelius B, Hoffmann K, Sjöden P-O, et al.  Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600
  118. Frey C, Twomey P, Kheen R, Elliot D, Higgins G. Randomized study of 5-fluorouracil and CCNU in pancreatic cancer. Cancer. 1981;47:27–31
  119. Andersen J, Friis-Moller A, Hancke S, Roder O, Steen J, Baden H. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand J Gastroenterol. 1981;16:973–975
  120. Andren-Sandberg A, Holmberg J, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU. Scand J Gastroenterol. 1983;18:609–612
  121. Mallinson CN, Rake MO, Cocking JB, et al.  Chemotherapy in pancreatic cancer: results of a controlled, randomised, multicenter trial. Br Med J. 1980;281:1589–1591
  122. Nicolson M, Webb A, Cunningham D, et al.  Cisplatin and protracted venous infusion 5-fluorouracil (CF)—good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol. 1995;6:801–804
  123. Andersen JS, Burris HA, Casper ES, et al.  Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. In: second edition. Proc Am Soc Clin Oncol. 13:1994;p. 461; (abstract 1600)
  124. Glimelius B, Hoffmann K, Graf W, et al.  Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995;6:267–274

PII: S0305-7372(98)90079-2

Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 133-156 , April 1998

Article Tools